Shire Appoints Susan Kilsby as Its New Chairman Effective April 2014 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Shire Appoints Susan Kilsby as Its New Chairman Effective April 2014



Shire has reported that Matthew Emmens will retire as non-executive chairman and Susan Kilsby, chairman of Shire’s Audit, Compliance & Risk Committee, will succeed him after the conclusion of Shire’s AGM on April 29, 2014. Emmens joined the company as chief executive in 2003 and became chairman of Shire in 2008. Kilsby joined the Shire Board as a non-executive director in September 2011. In May 2013, she was appointed chairman of Shire’s Audit, Compliance & Risk Committee. Dominic Blakemore will replace Kilsby’s position as chairman of Shire’s Audit, Compliance & Risk Committee. In addition, Kilsby’s will become a member of Shire’s Nomination Committee, effective February 1, 2014.

Source: Shire

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
25%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
11%
Regulatory compliance
36%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here